US 12,011,469 B2
Parenteral delivery device and methods of use
Mark C. Faulkner, Madison, TN (US); and Deeannah Seymour, Franklin, TN (US)
Assigned to Vireo Systems, Inc., Madison, TN (US)
Filed by Vireo Systems, Inc., Madison, TN (US)
Filed on May 23, 2018, as Appl. No. 15/987,729.
Claims priority of provisional application 62/509,841, filed on May 23, 2017.
Prior Publication US 2018/0339003 A1, Nov. 29, 2018
Int. Cl. A61K 35/747 (2015.01); A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/48 (2006.01); A61K 31/702 (2006.01); A61K 33/22 (2006.01); A61P 31/10 (2006.01); A61K 47/02 (2006.01)
CPC A61K 35/747 (2013.01) [A61K 9/0034 (2013.01); A61K 9/02 (2013.01); A61K 9/48 (2013.01); A61K 9/4825 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 31/702 (2013.01); A61K 33/22 (2013.01); A61P 31/10 (2018.01); A61K 47/02 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A delivery device, comprising:
a first compartment comprising a synbiotic, wherein the synbiotic comprises about 75 mg to about 125 mg by weight of a dry prebiotic and about 100 mg to about 450 mg by weight of a dry probiotic, wherein the dry probiotic comprises Lactobacillus Iners, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii, or combinations thereof;
a second compartment comprising a slurry, wherein the slurry consists of about 50 mg to about 600 mg hydrogen borate and about 150 mg to about 580 mg of an oil medium, and wherein the second compartment is disposed about the first compartment.